AG˹ٷ

STOCK TITAN

[424B2] Citigroup Inc. Prospectus Supplement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) Q3 FY-2025 Form 10-Q highlights

  • Revenue: $174 k for the quarter (+107% y/y); $532 k for nine months (+40% y/y). 98% of YTD sales stem from two IP-licensing customers.
  • Profitability: Q3 net loss widened to $3.79 m (-113% y/y). Nine-month net loss rose to $9.21 m (-155% y/y) as R&D spending accelerated to $6.36 m (+356%). Basic/diluted loss per share: $0.53 YTD.
  • Cash & Liquidity: Cash fell to $4.59 m from $6.50 m at FY-2024 year-end. Operating cash burn YTD: $7.81 m (vs $3.07 m prior year). Company raised $6.05 m net via two registered direct offerings and limited ATM activity, boosting shares outstanding to 19.56 m (+24%).
  • Balance Sheet: Total assets declined 24% to $6.74 m; equity fell 33% to $5.17 m. Working capital: $4.32 m. Warrants outstanding: 7.30 m (WAEP $3.75); options: 1.48 m (WAEP $2.29).
  • Going Concern: Management states “substantial doubt� about ability to continue operations beyond 12 months without additional capital, though current cash is expected to last through Q3 FY-2026.
  • Pipeline Progress: DehydraTECH drug-delivery platform advanced with multiple GLP-1 studies:
    • Completed 9-subject tirzepatide pilot; reported 47% fewer adverse events vs Zepbound®.
    • Finished dosing in 5-arm 12-week Australian Phase 1b (semaglutide, tirzepatide, CBD); results expected Q4 CY-2025.
    • Finished 10-subject liraglutide pilot; 23% fewer AEs vs Saxenda®.
    • Obese-rat study and biodistribution work ongoing.
  • Financings & Capital Markets: Oct-2024 $5 m gross (shares @ $3.06) with 4.55 m five-year warrants; Apr-2025 $2 m gross (shares @ $1.00) plus 70 k warrants.
  • Customer & Segment Data: Two customers account for 100% of revenue; business segments: Intellectual Property, B2B Production, R&D, Corporate.

Outlook: Lexaria plans further clinical work under its GLP-1/CBD programs and a Phase 1b hypertension study (FDA IND cleared but unfunded). Continuation is contingent on securing additional equity, debt or partnership funding; otherwise, cost-cutting or asset sales may ensue.

Lexaria Bioscience Corp. (NASDAQ: LEXX) evidenze del Form 10-Q del terzo trimestre dell'anno fiscale 2025

  • Ricavi: 174 mila dollari nel trimestre (+107% su base annua); 532 mila dollari nei primi nove mesi (+40% su base annua). Il 98% delle vendite YTD deriva da due clienti di licenze IP.
  • 徱پà: La perdita netta del terzo trimestre si è ampliata a 3,79 milioni di dollari (-113% su base annua). La perdita netta nei nove mesi è aumentata a 9,21 milioni di dollari (-155% su base annua) a causa di una crescita della spesa in R&S a 6,36 milioni di dollari (+356%). Perdita base/diluita per azione: 0,53 dollari YTD.
  • Liquidità e cassa: La cassa è scesa a 4,59 milioni di dollari da 6,50 milioni di fine anno fiscale 2024. Il consumo operativo di cassa YTD è stato di 7,81 milioni (rispetto a 3,07 milioni dell’anno precedente). La società ha raccolto 6,05 milioni netti tramite due offerte dirette registrate e attività ATM limitata, aumentando le azioni in circolazione a 19,56 milioni (+24%).
  • Bilancio: Gli attivi totali sono diminuiti del 24% a 6,74 milioni; il patrimonio netto è sceso del 33% a 5,17 milioni. Capitale circolante: 4,32 milioni. Warrant in circolazione: 7,30 milioni (prezzo medio di esercizio 3,75$); opzioni: 1,48 milioni (prezzo medio di esercizio 2,29$).
  • Continuità aziendale: Il management esprime “dubbio sostanziale� sulla capacità di proseguire le operazioni oltre 12 mesi senza capitale aggiuntivo, sebbene la cassa attuale dovrebbe coprire fino al terzo trimestre dell’anno fiscale 2026.
  • Progresso pipeline: La piattaforma di somministrazione DehydraTECH è avanzata con diversi studi su GLP-1:
    • Concluso un pilota con 9 soggetti su tirzepatide; segnalati il 47% in meno di eventi avversi rispetto a Zepbound®.
    • Completata la somministrazione in uno studio australiano di fase 1b a 5 bracci di 12 settimane (semaglutide, tirzepatide, CBD); risultati attesi nel quarto trimestre del 2025.
    • Terminato il pilota con 10 soggetti su liraglutide; 23% in meno di eventi avversi rispetto a Saxenda®.
    • In corso studi su ratti obesi e lavori di biodistribuzione.
  • Finanziamenti e mercati capitali: Ottobre 2024: 5 milioni lordi (azioni a 3,06$) con 4,55 milioni di warrant quinquennali; Aprile 2025: 2 milioni lordi (azioni a 1,00$) più 70 mila warrant.
  • Dati clienti e segmenti: Due clienti rappresentano il 100% dei ricavi; segmenti di business: Proprietà Intellettuale, Produzione B2B, R&S, Corporate.

Prospettive: Lexaria prevede ulteriori attività cliniche nei programmi GLP-1/CBD e uno studio di fase 1b sull’ipertensione (IND FDA approvato ma non finanziato). La prosecuzione dipende dall’ottenimento di ulteriori finanziamenti tramite equity, debito o partnership; in caso contrario, potrebbero essere adottate misure di riduzione dei costi o vendita di asset.

Lexaria Bioscience Corp. (NASDAQ: LEXX) aspectos destacados del Formulario 10-Q del tercer trimestre del año fiscal 2025

  • Ingresos: 174 mil dólares en el trimestre (+107% interanual); 532 mil dólares en nueve meses (+40% interanual). El 98% de las ventas acumuladas provienen de dos clientes de licencias de propiedad intelectual.
  • Rentabilidad: La pérdida neta del tercer trimestre se amplió a 3,79 millones de dólares (-113% interanual). La pérdida neta en nueve meses aumentó a 9,21 millones (-155% interanual) debido a un aumento en gastos de I+D a 6,36 millones (+356%). Pérdida básica/diluida por acción: 0,53 dólares acumulados.
  • Liquidez y efectivo: El efectivo disminuyó a 4,59 millones desde 6,50 millones al cierre del año fiscal 2024. Quema operativa de efectivo acumulada: 7,81 millones (vs 3,07 millones año anterior). La empresa recaudó 6,05 millones netos mediante dos ofertas directas registradas y actividad ATM limitada, aumentando las acciones en circulación a 19,56 millones (+24%).
  • Balance: Los activos totales bajaron 24% a 6,74 millones; el patrimonio cayó 33% a 5,17 millones. Capital de trabajo: 4,32 millones. Warrants en circulación: 7,30 millones (precio promedio de ejercicio 3,75$); opciones: 1,48 millones (precio promedio de ejercicio 2,29$).
  • Continuidad operativa: La dirección declara “duda sustancial� sobre la capacidad para continuar operaciones más allá de 12 meses sin capital adicional, aunque el efectivo actual debería cubrir hasta el tercer trimestre del año fiscal 2026.
  • Progreso en la cartera: La plataforma de administración DehydraTECH avanzó con múltiples estudios GLP-1:
    • Finalizado piloto con 9 sujetos de tirzepatida; reportó un 47% menos de eventos adversos comparado con Zepbound®.
    • Completada dosificación en estudio australiano de fase 1b de 5 brazos y 12 semanas (semaglutida, tirzepatida, CBD); resultados esperados en Q4 2025.
    • Finalizado piloto con 10 sujetos de liraglutida; 23% menos de eventos adversos que Saxenda®.
    • Estudio en ratas obesas y trabajos de biodistribución en curso.
  • Financiamientos y mercados de capital: Octubre 2024: 5 millones brutos (acciones a 3,06$) con 4,55 millones de warrants a cinco años; Abril 2025: 2 millones brutos (acciones a 1,00$) más 70 mil warrants.
  • Datos de clientes y segmentos: Dos clientes representan el 100% de los ingresos; segmentos de negocio: Propiedad Intelectual, Producción B2B, I+D, Corporativo.

Perspectivas: Lexaria planea continuar trabajos clínicos en sus programas GLP-1/CBD y un estudio de fase 1b para hipertensión (IND aprobado por FDA pero sin financiamiento). La continuidad depende de obtener financiamiento adicional vía capital, deuda o alianzas; de lo contrario, se considerarían recortes de costos o venta de activos.

Lexaria Bioscience Corp. (NASDAQ: LEXX) 2025 회계연도 3분기 Form 10-Q 주요 내용

  • 매출: 분기� 17� 4� 달러 (+전년 동기 대� 107%); 9개월 누적 53� 2� 달러 (+전년 동기 대� 40%). 연초부� 현재까지 매출� 98%� � IP 라이선스 고객에서 발생.
  • 수익�: 3분기 순손실은 379� 달러� 확대 (-전년 동기 대� 113%). 9개월 누적 순손실은 921� 달러� 증가 (-전년 동기 대� 155%)하며, 연구개발비는 636� 달러� 급증 (+356%). 기본 � 희석 손실 주당 0.53달러 누적.
  • 현금 � 유동�: 현금 잔액은 2024 회계연도 � 650� 달러에서 459� 달러� 감소. 연초 대� 운영 현금 소진은 781� 달러 (전년 307� 달러 대�). 회사� � 차례� 등록 직접공모와 제한� ATM 활동� 통해 � 605� 달러 조달, 발행 주식 수는 1,956� 주로 24% 증가.
  • 재무�: � 자산은 24% 감소� 674� 달러, 자본은 33% 감소� 517� 달러. 운전자본은 432� 달러. 워런� 발행 잔여� 730� � (평균 행사 가� 3.75달러), 옵션 148� � (평균 행사 가� 2.29달러).
  • 계속기업 가�: 경영진은 추가 자본 없이� 12개월 이상 운영 지속에 대� “상당한 의문”을 표명하였으나, 현재 현금은 2026 회계연도 3분기까지� 충분� 것으� 예상.
  • 파이프라� 진행 상황: DehydraTECH 약물 전달 플랫폼이 다수� GLP-1 연구와 함께 진전�:
    • 9� 대� 티르제파타이드 파일� 완료; Zepbound® 대� 부작용 47% 감소 보고.
    • 호주 5� 12� 1b�(세마글루타이드, 티르제파타이드, CBD) 투여 완료; 결과� 2025� 4분기 예정.
    • 10� 대� 리라글루타이드 파일� 완료; Saxenda® 대� 부작용 23% 감소.
    • 비만 � 연구 � 생체 분포 연구 진행 �.
  • 재무 조달 � 자본 시장: 2024� 10� 500� 달러 총액(주당 3.06달러) � 455� � 5� 만기 워런�; 2025� 4� 200� 달러 총액(주당 1.00달러) � 7� � 워런� 발행.
  • 고객 � 사업 부� 데이�: � 고객� 매출� 100% 차지; 사업 부문은 지� 재산�, B2B 생산, 연구개발, 기업부�.

전망: Lexaria� GLP-1/CBD 프로그램� 1b� 고혈� 연구(FDA IND 승인, 자금 미확�)� 계속 진행� 계획�. 추가 자본 조달(주식, 부�, 파트너십)� 필요하며, 확보 실패 � 비용 절감 또는 자산 매각 가능성 있음.

Lexaria Bioscience Corp. (NASDAQ : LEXX) faits saillants du formulaire 10-Q du troisième trimestre de l’exercice 2025

  • Revenus : 174 K$ pour le trimestre (+107 % en glissement annuel) ; 532 K$ pour neuf mois (+40 % en glissement annuel). 98 % des ventes cumulées proviennent de deux clients sous licence IP.
  • Rentabilité : La perte nette du T3 s’est creusée à 3,79 M$ (-113 % en glissement annuel). La perte nette sur neuf mois a augmenté à 9,21 M$ (-155 % en glissement annuel) en raison d’une accélération des dépenses R&D à 6,36 M$ (+356 %). Perte de base/diluée par action : 0,53 $ YTD.
  • Trésorerie et liquidités : La trésorerie est passée à 4,59 M$ contre 6,50 M$ à la fin de l’exercice 2024. Consommation de trésorerie opérationnelle YTD : 7,81 M$ (contre 3,07 M$ l’année précédente). La société a levé 6,05 M$ nets via deux offres directes enregistrées et une activité ATM limitée, portant le nombre d’actions en circulation à 19,56 M (+24 %).
  • Bilan : Les actifs totaux ont diminué de 24 % à 6,74 M$ ; les capitaux propres ont chuté de 33 % à 5,17 M$. Fonds de roulement : 4,32 M$. Warrants en circulation : 7,30 M (prix moyen d’exercice 3,75 $) ; options : 1,48 M (prix moyen d’exercice 2,29 $).
  • Continuité d’exploitation : La direction exprime un « doute substantiel » quant à la capacité de poursuivre les opérations au-delà de 12 mois sans capitaux additionnels, bien que la trésorerie actuelle devrait suffire jusqu’au T3 de l’exercice 2026.
  • Progrès du pipeline : La plateforme de délivrance DehydraTECH a progressé avec plusieurs études GLP-1 :
    • Essai pilote avec 9 sujets sur le tirzepatide terminé ; 47 % d’effets indésirables en moins par rapport à Zepbound®.
    • Fin du dosage dans une étude australienne de phase 1b à 5 bras sur 12 semaines (sémaglutide, tirzepatide, CBD) ; résultats attendus au T4 2025.
    • Essai pilote avec 10 sujets sur le liraglutide terminé ; 23 % d’effets indésirables en moins par rapport à Saxenda®.
    • Étude sur des rats obèses et travaux de biodistribution en cours.
  • Financements et marchés financiers : Octobre 2024 : 5 M$ brut (actions à 3,06 $) avec 4,55 M de warrants sur cinq ans ; avril 2025 : 2 M$ brut (actions à 1,00 $) plus 70 k warrants.
  • Données clients et segments : Deux clients représentent 100 % des revenus ; segments d’activité : propriété intellectuelle, production B2B, R&D, corporate.

Perspectives : Lexaria prévoit de poursuivre les travaux cliniques dans ses programmes GLP-1/CBD et une étude de phase 1b sur l’hypertension (IND FDA approuvé mais non financé). La poursuite dépendra de l’obtention de financements supplémentaires en fonds propres, dette ou partenariats ; sinon, des mesures de réduction des coûts ou des cessions d’actifs pourraient être envisagées.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights des Form 10-Q für das 3. Quartal des Geschäftsjahres 2025

  • Umsatz: 174.000 USD im Quartal (+107 % gegenüber Vorjahr); 532.000 USD in neun Monaten (+40 % gegenüber Vorjahr). 98 % der Umsätze im laufenden Jahr stammen von zwei IP-Lizenzkunden.
  • Գٲä: Der Nettoverlust im 3. Quartal stieg auf 3,79 Mio. USD (-113 % gegenüber Vorjahr). Der Nettoverlust in neun Monaten erhöhte sich auf 9,21 Mio. USD (-155 % gegenüber Vorjahr), da die F&E-Ausgaben auf 6,36 Mio. USD (+356 %) beschleunigten. Grundlegender/verwässerter Verlust je Aktie: 0,53 USD im laufenden Jahr.
  • Barmittel & Liquidität: Der Kassenbestand sank von 6,50 Mio. USD zum Geschäftsjahresende 2024 auf 4,59 Mio. USD. Operativer Cashburn im laufenden Jahr: 7,81 Mio. USD (gegenüber 3,07 Mio. USD im Vorjahr). Das Unternehmen erzielte netto 6,05 Mio. USD durch zwei registrierte Direktangebote und begrenzte ATM-Aktivitäten, wodurch die ausstehenden Aktien um 24 % auf 19,56 Mio. stiegen.
  • Bilanz: Die Gesamtaktiva sanken um 24 % auf 6,74 Mio. USD; das Eigenkapital fiel um 33 % auf 5,17 Mio. USD. Umlaufvermögen: 4,32 Mio. USD. Ausstehende Warrants: 7,30 Mio. (durchschnittlicher Ausübungspreis 3,75 USD); Optionen: 1,48 Mio. (durchschnittlicher Ausübungspreis 2,29 USD).
  • ǰٴüܲԲDzԴDz: Das Management äußert „erhebliche Zweifel� an der Fähigkeit, den Betrieb ohne zusätzliches Kapital über 12 Monate hinaus fortzuführen, erwartet jedoch, dass die aktuellen Barmittel bis zum 3. Quartal des Geschäftsjahres 2026 ausreichen.
  • Pipeline-Fortschritt: Die DehydraTECH-Wirkstoffabgabetechnologie wurde mit mehreren GLP-1-Studien vorangetrieben:
    • Abschluss einer Pilotstudie mit 9 Probanden zu Tirzepatid; berichtete 47 % weniger Nebenwirkungen im Vergleich zu Zepbound®.
    • Abschluss der Dosierung in einer 5-armigen 12-wöchigen australischen Phase-1b-Studie (Semaglutid, Tirzepatid, CBD); Ergebnisse erwartet im 4. Quartal 2025.
    • Abschluss einer Pilotstudie mit 10 Probanden zu Liraglutid; 23 % weniger Nebenwirkungen als bei Saxenda®.
    • Studien mit fettleibigen Ratten und Biodistributionsarbeiten laufen.
  • Finanzierungen & Kapitalmärkte: Oktober 2024: Brutto 5 Mio. USD (Aktien zu 3,06 USD) mit 4,55 Mio. Warrants über fünf Jahre; April 2025: Brutto 2 Mio. USD (Aktien zu 1,00 USD) plus 70.000 Warrants.
  • Kunden- & Segmentdaten: Zwei Kunden machen 100 % des Umsatzes aus; Geschäftssegmente: Geistiges Eigentum, B2B-Produktion, F&E, Unternehmensbereich.

Ausblick: Lexaria plant weitere klinische Studien im Rahmen seiner GLP-1/CBD-Programme sowie eine Phase-1b-Studie zur Hypertonie (FDA-IND genehmigt, aber nicht finanziert). Die Fortsetzung hängt von zusätzlicher Eigenkapital-, Fremd- oder Partnerschaftsfinanzierung ab; andernfalls könnten Kostensenkungen oder Vermögensverkäufe folgen.

Positive
  • Revenue growth: Q3 sales up 107% y/y and nine-month revenue up 40%, driven by IP licensing fees.
  • Capital raised: $6.05 m net equity funding extends cash runway to Q3 FY-2026.
  • Clinical progress: Positive tolerability data from human pilot studies with DehydraTECH-tirzepatide and -liraglutide; Phase 1b 5-arm study fully enrolled.
  • Extensive patent portfolio: 37 granted patents, including new GLP-1 delivery claims, strengthening competitive moat.
Negative
  • Widening losses: Nine-month net loss increased to $9.2 m (-155% y/y) due to 356% surge in R&D expenses.
  • Cash burn: Operating cash outflow of $7.8 m YTD reduced cash to $4.6 m.
  • Going-concern doubt: Management warns existing resources are insufficient for 12 months beyond filing date.
  • Dilution risk: Share count up 24% in nine months; 7.3 m warrants outstanding could add further dilution.
  • Customer concentration: Two licensees represent 100% of revenue, exposing the firm to counter-party risk.

Insights

TL;DR: Cash burn, rising losses and going-concern warning outweigh modest revenue growth and pipeline advances.

Revenue doubled in the quarter but remains immaterial ($174 k). Meanwhile R&D spend quadrupled, pushing the nine-month operating loss above $9 m and depleting cash to $4.6 m. The company financed operations by issuing 3.7 m new shares and 4.6 m warrants, diluting holders by ~24%. Management expects cash to fund activities for roughly 12�15 months, yet explicitly states that funding is insufficient for the full going-concern horizon. Thus, further dilution or alternative financing is likely. From a valuation standpoint, the balance sheet offers limited downside protection and no near-term revenue catalysts appear capable of offsetting burn. I see the filing as negative for equity holders.

TL;DR: Clinical readouts show tolerability edge for oral GLP-1 formulations, but financial runway is thin.

Lexaria’s DehydraTECH technology produced encouraging head-to-head data versus injectable liraglutide and tirzepatide: 23-47% fewer adverse events with comparable glycemic and weight outcomes. If replicated in the ongoing 120-patient Phase 1b, these findings may enable a 505(b)(2) path—potentially shortening time-to-market and attracting partners. The patent estate now spans 37 grants across multiple geographies, offering defensibility. However, transitioning from proof-of-concept to registrational studies will require substantially greater capital and an experienced pharma collaborator. Absent such a deal, Lexaria’s capacity to exploit its IP remains constrained. I classify the update as neutral—scientifically promising but financially uncertain.

Lexaria Bioscience Corp. (NASDAQ: LEXX) evidenze del Form 10-Q del terzo trimestre dell'anno fiscale 2025

  • Ricavi: 174 mila dollari nel trimestre (+107% su base annua); 532 mila dollari nei primi nove mesi (+40% su base annua). Il 98% delle vendite YTD deriva da due clienti di licenze IP.
  • 徱پà: La perdita netta del terzo trimestre si è ampliata a 3,79 milioni di dollari (-113% su base annua). La perdita netta nei nove mesi è aumentata a 9,21 milioni di dollari (-155% su base annua) a causa di una crescita della spesa in R&S a 6,36 milioni di dollari (+356%). Perdita base/diluita per azione: 0,53 dollari YTD.
  • Liquidità e cassa: La cassa è scesa a 4,59 milioni di dollari da 6,50 milioni di fine anno fiscale 2024. Il consumo operativo di cassa YTD è stato di 7,81 milioni (rispetto a 3,07 milioni dell’anno precedente). La società ha raccolto 6,05 milioni netti tramite due offerte dirette registrate e attività ATM limitata, aumentando le azioni in circolazione a 19,56 milioni (+24%).
  • Bilancio: Gli attivi totali sono diminuiti del 24% a 6,74 milioni; il patrimonio netto è sceso del 33% a 5,17 milioni. Capitale circolante: 4,32 milioni. Warrant in circolazione: 7,30 milioni (prezzo medio di esercizio 3,75$); opzioni: 1,48 milioni (prezzo medio di esercizio 2,29$).
  • Continuità aziendale: Il management esprime “dubbio sostanziale� sulla capacità di proseguire le operazioni oltre 12 mesi senza capitale aggiuntivo, sebbene la cassa attuale dovrebbe coprire fino al terzo trimestre dell’anno fiscale 2026.
  • Progresso pipeline: La piattaforma di somministrazione DehydraTECH è avanzata con diversi studi su GLP-1:
    • Concluso un pilota con 9 soggetti su tirzepatide; segnalati il 47% in meno di eventi avversi rispetto a Zepbound®.
    • Completata la somministrazione in uno studio australiano di fase 1b a 5 bracci di 12 settimane (semaglutide, tirzepatide, CBD); risultati attesi nel quarto trimestre del 2025.
    • Terminato il pilota con 10 soggetti su liraglutide; 23% in meno di eventi avversi rispetto a Saxenda®.
    • In corso studi su ratti obesi e lavori di biodistribuzione.
  • Finanziamenti e mercati capitali: Ottobre 2024: 5 milioni lordi (azioni a 3,06$) con 4,55 milioni di warrant quinquennali; Aprile 2025: 2 milioni lordi (azioni a 1,00$) più 70 mila warrant.
  • Dati clienti e segmenti: Due clienti rappresentano il 100% dei ricavi; segmenti di business: Proprietà Intellettuale, Produzione B2B, R&S, Corporate.

Prospettive: Lexaria prevede ulteriori attività cliniche nei programmi GLP-1/CBD e uno studio di fase 1b sull’ipertensione (IND FDA approvato ma non finanziato). La prosecuzione dipende dall’ottenimento di ulteriori finanziamenti tramite equity, debito o partnership; in caso contrario, potrebbero essere adottate misure di riduzione dei costi o vendita di asset.

Lexaria Bioscience Corp. (NASDAQ: LEXX) aspectos destacados del Formulario 10-Q del tercer trimestre del año fiscal 2025

  • Ingresos: 174 mil dólares en el trimestre (+107% interanual); 532 mil dólares en nueve meses (+40% interanual). El 98% de las ventas acumuladas provienen de dos clientes de licencias de propiedad intelectual.
  • Rentabilidad: La pérdida neta del tercer trimestre se amplió a 3,79 millones de dólares (-113% interanual). La pérdida neta en nueve meses aumentó a 9,21 millones (-155% interanual) debido a un aumento en gastos de I+D a 6,36 millones (+356%). Pérdida básica/diluida por acción: 0,53 dólares acumulados.
  • Liquidez y efectivo: El efectivo disminuyó a 4,59 millones desde 6,50 millones al cierre del año fiscal 2024. Quema operativa de efectivo acumulada: 7,81 millones (vs 3,07 millones año anterior). La empresa recaudó 6,05 millones netos mediante dos ofertas directas registradas y actividad ATM limitada, aumentando las acciones en circulación a 19,56 millones (+24%).
  • Balance: Los activos totales bajaron 24% a 6,74 millones; el patrimonio cayó 33% a 5,17 millones. Capital de trabajo: 4,32 millones. Warrants en circulación: 7,30 millones (precio promedio de ejercicio 3,75$); opciones: 1,48 millones (precio promedio de ejercicio 2,29$).
  • Continuidad operativa: La dirección declara “duda sustancial� sobre la capacidad para continuar operaciones más allá de 12 meses sin capital adicional, aunque el efectivo actual debería cubrir hasta el tercer trimestre del año fiscal 2026.
  • Progreso en la cartera: La plataforma de administración DehydraTECH avanzó con múltiples estudios GLP-1:
    • Finalizado piloto con 9 sujetos de tirzepatida; reportó un 47% menos de eventos adversos comparado con Zepbound®.
    • Completada dosificación en estudio australiano de fase 1b de 5 brazos y 12 semanas (semaglutida, tirzepatida, CBD); resultados esperados en Q4 2025.
    • Finalizado piloto con 10 sujetos de liraglutida; 23% menos de eventos adversos que Saxenda®.
    • Estudio en ratas obesas y trabajos de biodistribución en curso.
  • Financiamientos y mercados de capital: Octubre 2024: 5 millones brutos (acciones a 3,06$) con 4,55 millones de warrants a cinco años; Abril 2025: 2 millones brutos (acciones a 1,00$) más 70 mil warrants.
  • Datos de clientes y segmentos: Dos clientes representan el 100% de los ingresos; segmentos de negocio: Propiedad Intelectual, Producción B2B, I+D, Corporativo.

Perspectivas: Lexaria planea continuar trabajos clínicos en sus programas GLP-1/CBD y un estudio de fase 1b para hipertensión (IND aprobado por FDA pero sin financiamiento). La continuidad depende de obtener financiamiento adicional vía capital, deuda o alianzas; de lo contrario, se considerarían recortes de costos o venta de activos.

Lexaria Bioscience Corp. (NASDAQ: LEXX) 2025 회계연도 3분기 Form 10-Q 주요 내용

  • 매출: 분기� 17� 4� 달러 (+전년 동기 대� 107%); 9개월 누적 53� 2� 달러 (+전년 동기 대� 40%). 연초부� 현재까지 매출� 98%� � IP 라이선스 고객에서 발생.
  • 수익�: 3분기 순손실은 379� 달러� 확대 (-전년 동기 대� 113%). 9개월 누적 순손실은 921� 달러� 증가 (-전년 동기 대� 155%)하며, 연구개발비는 636� 달러� 급증 (+356%). 기본 � 희석 손실 주당 0.53달러 누적.
  • 현금 � 유동�: 현금 잔액은 2024 회계연도 � 650� 달러에서 459� 달러� 감소. 연초 대� 운영 현금 소진은 781� 달러 (전년 307� 달러 대�). 회사� � 차례� 등록 직접공모와 제한� ATM 활동� 통해 � 605� 달러 조달, 발행 주식 수는 1,956� 주로 24% 증가.
  • 재무�: � 자산은 24% 감소� 674� 달러, 자본은 33% 감소� 517� 달러. 운전자본은 432� 달러. 워런� 발행 잔여� 730� � (평균 행사 가� 3.75달러), 옵션 148� � (평균 행사 가� 2.29달러).
  • 계속기업 가�: 경영진은 추가 자본 없이� 12개월 이상 운영 지속에 대� “상당한 의문”을 표명하였으나, 현재 현금은 2026 회계연도 3분기까지� 충분� 것으� 예상.
  • 파이프라� 진행 상황: DehydraTECH 약물 전달 플랫폼이 다수� GLP-1 연구와 함께 진전�:
    • 9� 대� 티르제파타이드 파일� 완료; Zepbound® 대� 부작용 47% 감소 보고.
    • 호주 5� 12� 1b�(세마글루타이드, 티르제파타이드, CBD) 투여 완료; 결과� 2025� 4분기 예정.
    • 10� 대� 리라글루타이드 파일� 완료; Saxenda® 대� 부작용 23% 감소.
    • 비만 � 연구 � 생체 분포 연구 진행 �.
  • 재무 조달 � 자본 시장: 2024� 10� 500� 달러 총액(주당 3.06달러) � 455� � 5� 만기 워런�; 2025� 4� 200� 달러 총액(주당 1.00달러) � 7� � 워런� 발행.
  • 고객 � 사업 부� 데이�: � 고객� 매출� 100% 차지; 사업 부문은 지� 재산�, B2B 생산, 연구개발, 기업부�.

전망: Lexaria� GLP-1/CBD 프로그램� 1b� 고혈� 연구(FDA IND 승인, 자금 미확�)� 계속 진행� 계획�. 추가 자본 조달(주식, 부�, 파트너십)� 필요하며, 확보 실패 � 비용 절감 또는 자산 매각 가능성 있음.

Lexaria Bioscience Corp. (NASDAQ : LEXX) faits saillants du formulaire 10-Q du troisième trimestre de l’exercice 2025

  • Revenus : 174 K$ pour le trimestre (+107 % en glissement annuel) ; 532 K$ pour neuf mois (+40 % en glissement annuel). 98 % des ventes cumulées proviennent de deux clients sous licence IP.
  • Rentabilité : La perte nette du T3 s’est creusée à 3,79 M$ (-113 % en glissement annuel). La perte nette sur neuf mois a augmenté à 9,21 M$ (-155 % en glissement annuel) en raison d’une accélération des dépenses R&D à 6,36 M$ (+356 %). Perte de base/diluée par action : 0,53 $ YTD.
  • Trésorerie et liquidités : La trésorerie est passée à 4,59 M$ contre 6,50 M$ à la fin de l’exercice 2024. Consommation de trésorerie opérationnelle YTD : 7,81 M$ (contre 3,07 M$ l’année précédente). La société a levé 6,05 M$ nets via deux offres directes enregistrées et une activité ATM limitée, portant le nombre d’actions en circulation à 19,56 M (+24 %).
  • Bilan : Les actifs totaux ont diminué de 24 % à 6,74 M$ ; les capitaux propres ont chuté de 33 % à 5,17 M$. Fonds de roulement : 4,32 M$. Warrants en circulation : 7,30 M (prix moyen d’exercice 3,75 $) ; options : 1,48 M (prix moyen d’exercice 2,29 $).
  • Continuité d’exploitation : La direction exprime un « doute substantiel » quant à la capacité de poursuivre les opérations au-delà de 12 mois sans capitaux additionnels, bien que la trésorerie actuelle devrait suffire jusqu’au T3 de l’exercice 2026.
  • Progrès du pipeline : La plateforme de délivrance DehydraTECH a progressé avec plusieurs études GLP-1 :
    • Essai pilote avec 9 sujets sur le tirzepatide terminé ; 47 % d’effets indésirables en moins par rapport à Zepbound®.
    • Fin du dosage dans une étude australienne de phase 1b à 5 bras sur 12 semaines (sémaglutide, tirzepatide, CBD) ; résultats attendus au T4 2025.
    • Essai pilote avec 10 sujets sur le liraglutide terminé ; 23 % d’effets indésirables en moins par rapport à Saxenda®.
    • Étude sur des rats obèses et travaux de biodistribution en cours.
  • Financements et marchés financiers : Octobre 2024 : 5 M$ brut (actions à 3,06 $) avec 4,55 M de warrants sur cinq ans ; avril 2025 : 2 M$ brut (actions à 1,00 $) plus 70 k warrants.
  • Données clients et segments : Deux clients représentent 100 % des revenus ; segments d’activité : propriété intellectuelle, production B2B, R&D, corporate.

Perspectives : Lexaria prévoit de poursuivre les travaux cliniques dans ses programmes GLP-1/CBD et une étude de phase 1b sur l’hypertension (IND FDA approuvé mais non financé). La poursuite dépendra de l’obtention de financements supplémentaires en fonds propres, dette ou partenariats ; sinon, des mesures de réduction des coûts ou des cessions d’actifs pourraient être envisagées.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights des Form 10-Q für das 3. Quartal des Geschäftsjahres 2025

  • Umsatz: 174.000 USD im Quartal (+107 % gegenüber Vorjahr); 532.000 USD in neun Monaten (+40 % gegenüber Vorjahr). 98 % der Umsätze im laufenden Jahr stammen von zwei IP-Lizenzkunden.
  • Գٲä: Der Nettoverlust im 3. Quartal stieg auf 3,79 Mio. USD (-113 % gegenüber Vorjahr). Der Nettoverlust in neun Monaten erhöhte sich auf 9,21 Mio. USD (-155 % gegenüber Vorjahr), da die F&E-Ausgaben auf 6,36 Mio. USD (+356 %) beschleunigten. Grundlegender/verwässerter Verlust je Aktie: 0,53 USD im laufenden Jahr.
  • Barmittel & Liquidität: Der Kassenbestand sank von 6,50 Mio. USD zum Geschäftsjahresende 2024 auf 4,59 Mio. USD. Operativer Cashburn im laufenden Jahr: 7,81 Mio. USD (gegenüber 3,07 Mio. USD im Vorjahr). Das Unternehmen erzielte netto 6,05 Mio. USD durch zwei registrierte Direktangebote und begrenzte ATM-Aktivitäten, wodurch die ausstehenden Aktien um 24 % auf 19,56 Mio. stiegen.
  • Bilanz: Die Gesamtaktiva sanken um 24 % auf 6,74 Mio. USD; das Eigenkapital fiel um 33 % auf 5,17 Mio. USD. Umlaufvermögen: 4,32 Mio. USD. Ausstehende Warrants: 7,30 Mio. (durchschnittlicher Ausübungspreis 3,75 USD); Optionen: 1,48 Mio. (durchschnittlicher Ausübungspreis 2,29 USD).
  • ǰٴüܲԲDzԴDz: Das Management äußert „erhebliche Zweifel� an der Fähigkeit, den Betrieb ohne zusätzliches Kapital über 12 Monate hinaus fortzuführen, erwartet jedoch, dass die aktuellen Barmittel bis zum 3. Quartal des Geschäftsjahres 2026 ausreichen.
  • Pipeline-Fortschritt: Die DehydraTECH-Wirkstoffabgabetechnologie wurde mit mehreren GLP-1-Studien vorangetrieben:
    • Abschluss einer Pilotstudie mit 9 Probanden zu Tirzepatid; berichtete 47 % weniger Nebenwirkungen im Vergleich zu Zepbound®.
    • Abschluss der Dosierung in einer 5-armigen 12-wöchigen australischen Phase-1b-Studie (Semaglutid, Tirzepatid, CBD); Ergebnisse erwartet im 4. Quartal 2025.
    • Abschluss einer Pilotstudie mit 10 Probanden zu Liraglutid; 23 % weniger Nebenwirkungen als bei Saxenda®.
    • Studien mit fettleibigen Ratten und Biodistributionsarbeiten laufen.
  • Finanzierungen & Kapitalmärkte: Oktober 2024: Brutto 5 Mio. USD (Aktien zu 3,06 USD) mit 4,55 Mio. Warrants über fünf Jahre; April 2025: Brutto 2 Mio. USD (Aktien zu 1,00 USD) plus 70.000 Warrants.
  • Kunden- & Segmentdaten: Zwei Kunden machen 100 % des Umsatzes aus; Geschäftssegmente: Geistiges Eigentum, B2B-Produktion, F&E, Unternehmensbereich.

Ausblick: Lexaria plant weitere klinische Studien im Rahmen seiner GLP-1/CBD-Programme sowie eine Phase-1b-Studie zur Hypertonie (FDA-IND genehmigt, aber nicht finanziert). Die Fortsetzung hängt von zusätzlicher Eigenkapital-, Fremd- oder Partnerschaftsfinanzierung ab; andernfalls könnten Kostensenkungen oder Vermögensverkäufe folgen.

The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, underlying supplement, prospectus supplement and prospectus are not an offer to sell these securities, nor are they soliciting an offer to buy these securities, in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JULY 11, 2025

Citigroup Global Markets Holdings Inc.

July     , 2025

Medium-Term Senior Notes, Series N

Pricing Supplement No. 2025-USNCH27578

Filed Pursuant to Rule 424(b)(2)

Registration Statement Nos. 333-270327 and 333-270327-01

Autocallable Securities Linked to the Worst Performing of the Nasdaq-100 Index®, the Russell 2000® Index and the S&P 500® Index Due July 26, 2028

The securities offered by this pricing supplement are unsecured debt securities issued by Citigroup Global Markets Holdings Inc. and guaranteed by Citigroup Inc. Unlike conventional debt securities, the securities do not pay interest, do not guarantee the repayment of principal at maturity and are subject to potential automatic early redemption on a periodic basis on the terms described below. Your return on the securities will depend solely on the performance of the worst performing of the underlyings specified below.

The securities offer the potential for automatic early redemption at a premium following the first valuation date (other than the final valuation date) on which the closing value of the worst performing underlying on that valuation date is greater than or equal to its initial underlying value. If the securities are not automatically redeemed prior to maturity, the securities will provide for (i) repayment of the stated principal amount plus a premium at maturity if the final underlying value of the worst performing underlying on the final valuation date is greater than or equal to its initial underlying value or (ii) repayment of the stated principal amount at maturity, with no premium, if the final underlying value of the worst performing underlying on the final valuation date is less than its initial underlying value but greater than or equal to its final barrier value specified below. However, if the securities are not automatically redeemed prior to maturity and the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value, you will lose 1% of the stated principal amount of your securities for every 1% by which its final underlying value is less than its initial underlying value.

You will be subject to risks associated with each of the underlyings and will be negatively affected by adverse movements in any one of the underlyings. Although you will have downside exposure to the worst performing underlying on the final valuation date, you will not receive dividends with respect to any underlying or participate in any appreciation of any underlying.

Investors in the securities must be willing to accept (i) an investment that may have limited or no liquidity and (ii) the risk of not receiving any payments due under the securities if we and Citigroup Inc. default on our obligations. All payments on the securities are subject to the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc.

 

KEY TERMS

Issuer:

Citigroup Global Markets Holdings Inc., a wholly owned subsidiary of Citigroup Inc.

Guarantee:

All payments due on the securities are fully and unconditionally guaranteed by Citigroup Inc.

Underlyings:

 

Underlying

Initial underlying value*

Final barrier value**

Nasdaq-100 Index®

 

 

Russell 2000® Index

 

 

S&P 500® Index

 

 

 

*For each underlying, its closing value on the pricing date

**For each underlying, 70.00% of its initial underlying value

Stated principal amount:

$1,000 per security

Pricing date:

July 21, 2025

Issue date:

July 24, 2025

Valuation dates:

July 22, 2026, August 21, 2026, September 21, 2026, October 21, 2026, November 23, 2026, December 21, 2026, January 21, 2027, February 22, 2027, March 22, 2027, April 21, 2027, May 21, 2027, June 21, 2027, July 21, 2027, August 23, 2027, September 21, 2027, October 21, 2027, November 22, 2027, December 21, 2027, January 21, 2028, February 22, 2028, March 21, 2028, April 21, 2028, May 22, 2028, June 21, 2028 and July 21, 2028 (the “final valuation date”), each subject to postponement if such date is not a scheduled trading day or certain market disruption events occur

Maturity date:

Unless earlier redeemed, July 26, 2028

Automatic early redemption:

If, on any valuation date prior to the final valuation date, the closing value of the worst performing underlying on that valuation date is greater than or equal to its initial underlying value, the securities will be automatically redeemed on the third business day immediately following that valuation date for an amount in cash per security equal to $1,000 plus the premium applicable to that valuation date. If the securities are automatically redeemed following any valuation date prior to the final valuation date, they will cease to be outstanding and you will not receive the premium applicable to any later valuation date.

Payment at maturity:

If the securities are not automatically redeemed prior to maturity, you will receive at maturity for each security you then hold:

If the final underlying value of the worst performing underlying on the final valuation date is greater than or equal to its initial underlying value: $1,000 + the premium applicable to the final valuation date

If the final underlying value of the worst performing underlying on the final valuation date is less than its initial underlying value but greater than or equal to its final barrier value: $1,000

If the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value:

$1,000 + ($1,000 × the underlying return of the worst performing underlying on the final valuation date)

If the securities are not automatically redeemed prior to maturity and the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value, you will receive significantly less than the stated principal amount of your securities, and possibly nothing, at maturity.

Listing:

The securities will not be listed on any securities exchange

Underwriter:

Citigroup Global Markets Inc. (“CGMI”), an affiliate of the issuer, acting as principal

Underwriting fee and issue price:

Issue price(1)

Underwriting fee(2)

Proceeds to issuer(3)

Per security:

$1,000.00

$27.50

$972.50

Total:

$

$

$

 

(Key Terms continued on next page)

(1) Citigroup Global Markets Holdings Inc. currently expects that the estimated value of the securities on the pricing date will be at least $914.00 per security, which will be less than the issue price. The estimated value of the securities is based on CGMI’s proprietary pricing models and our internal funding rate. It is not an indication of actual profit to CGMI or other of our affiliates, nor is it an indication of the price, if any, at which CGMI or any other person may be willing to buy the securities from you at any time after issuance. See “Valuation of the Securities” in this pricing supplement.

(2) CGMI will receive an underwriting fee of up to $27.50 for each security sold in this offering. The total underwriting fee and proceeds to issuer in the table above give effect to the actual total underwriting fee. For more information on the distribution of the securities, see “Supplemental Plan of Distribution” in this pricing supplement. In addition to the underwriting fee, CGMI and its affiliates may profit from expected hedging activity related to this offering, even if the value of the securities declines. See “Use of Proceeds and Hedging” in the accompanying prospectus.

(3) The per security proceeds to issuer indicated above represent the minimum per security proceeds to issuer for any security, assuming the maximum per security underwriting fee. As noted above, the underwriting fee is variable.

Investing in the securities involves risks not associated with an investment in conventional debt securities. See “Summary Risk Factors” beginning on page PS-8.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities or determined that this pricing supplement and the accompanying product supplement, underlying supplement, prospectus supplement and prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

You should read this pricing supplement together with the accompanying product supplement, underlying supplement, prospectus supplement and prospectus, which can be accessed via the hyperlinks below:

Product Supplement No. EA-02-10 dated March 7, 2023Underlying Supplement No. 11 dated March 7, 2023
Prospectus Supplement and Prospectus each dated March 7, 2023

The securities are not bank deposits and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency, nor are they obligations of, or guaranteed by, a bank.

 


 

Citigroup Global Markets Holdings Inc.

 

 

KEY TERMS (continued)

Premium:

The premium applicable to each valuation date is the percentage of the stated principal amount indicated below. The premium may be significantly less than the appreciation of any underlying from the pricing date to the applicable valuation date.

 

July 22, 2026:

11.50% of the stated principal amount

August 21, 2026:

12.4583% of the stated principal amount

September 21, 2026:

13.4167% of the stated principal amount

October 21, 2026:

14.375% of the stated principal amount

November 23, 2026:

15.3333% of the stated principal amount

December 21, 2026:

16.2917% of the stated principal amount

January 21, 2027:

17.25% of the stated principal amount

February 22, 2027:

18.2083% of the stated principal amount

March 22, 2027:

19.1667% of the stated principal amount

April 21, 2027:

20.125% of the stated principal amount

May 21, 2027:

21.0833% of the stated principal amount

June 21, 2027:

22.0417% of the stated principal amount

July 21, 2027:

23.00% of the stated principal amount

August 23, 2027:

23.9583% of the stated principal amount

September 21, 2027:

24.9167% of the stated principal amount

October 21, 2027:

25.875% of the stated principal amount

November 22, 2027:

26.8333% of the stated principal amount

December 21, 2027:

27.7917% of the stated principal amount

January 21, 2028:

28.75% of the stated principal amount

February 22, 2028:

29.7083% of the stated principal amount

March 21, 2028:

30.6667% of the stated principal amount

April 21, 2028:

31.625% of the stated principal amount

May 22, 2028:

32.5833% of the stated principal amount

June 21, 2028:

33.5417% of the stated principal amount

July 21, 2028:

34.50% of the stated principal amount

Final underlying value:

For each underlying, its closing value on the final valuation date

Worst performing underlying:

For any valuation date, the underlying with the lowest underlying return determined as of that valuation date

Underlying return:

For each underlying on any valuation date, (i) its closing value on that valuation date minus its initial underlying value, divided by (ii) its initial underlying value

CUSIP / ISIN:

17333LMU6 / US17333LMU60

 


 

Citigroup Global Markets Holdings Inc.

 

 

Additional Information

The terms of the securities are set forth in the accompanying product supplement, prospectus supplement and prospectus, as supplemented by this pricing supplement. The accompanying product supplement, prospectus supplement and prospectus contain important disclosures that are not repeated in this pricing supplement. For example, the accompanying product supplement contains important information about how the closing value of each underlying will be determined and about adjustments that may be made to the terms of the securities upon the occurrence of market disruption events and other specified events with respect to each underlying. The accompanying underlying supplement contains information about each underlying that is not repeated in this pricing supplement. It is important that you read the accompanying product supplement, underlying supplement, prospectus supplement and prospectus together with this pricing supplement before deciding whether to invest in the securities. Certain terms used but not defined in this pricing supplement are defined in the accompanying product supplement.

 


 

Citigroup Global Markets Holdings Inc.

 

 

Hypothetical Payment Upon Automatic Early Redemption

The following table illustrates how the amount payable per security upon automatic early redemption will be calculated if the closing value of the worst performing underlying on any valuation date prior to the final valuation date is greater than or equal to its initial underlying value.

 

If the first valuation date on which the closing value of the worst performing underlying on that valuation date is greater than or equal to its initial underlying value is...

...then you will receive the following payment per security upon automatic early redemption:

July 22, 2026 

$1,000.00 + applicable premium = $1,000.00 + $115.00 = $1,115.00

August 21, 2026 

$1,000.00 + applicable premium = $1,000.00 + $124.583 = $1,124.583

September 21, 2026 

$1,000.00 + applicable premium = $1,000.00 + $134.167 = $1,134.167

October 21, 2026 

$1,000.00 + applicable premium = $1,000.00 + $143.75 = $1,143.75

November 23, 2026 

$1,000.00 + applicable premium = $1,000.00 + $153.333 = $1,153.333

December 21, 2026 

$1,000.00 + applicable premium = $1,000.00 + $162.917 = $1,162.917

January 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $172.50 = $1,172.50

February 22, 2027 

$1,000.00 + applicable premium = $1,000.00 + $182.083 = $1,182.083

March 22, 2027 

$1,000.00 + applicable premium = $1,000.00 + $191.667 = $1,191.667

April 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $201.25 = $1,201.25

May 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $210.833 = $1,210.833

June 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $220.417 = $1,220.417

July 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $230.00 = $1,230.00

August 23, 2027 

$1,000.00 + applicable premium = $1,000.00 + $239.583 = $1,239.583

September 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $249.167 = $1,249.167

October 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $258.75 = $1,258.75

November 22, 2027 

$1,000.00 + applicable premium = $1,000.00 + $268.333 = $1,268.333

December 21, 2027 

$1,000.00 + applicable premium = $1,000.00 + $277.917 = $1,277.917

January 21, 2028 

$1,000.00 + applicable premium = $1,000.00 + $287.50 = $1,287.50

February 22, 2028 

$1,000.00 + applicable premium = $1,000.00 + $297.083 = $1,297.083

March 21, 2028 

$1,000.00 + applicable premium = $1,000.00 + $306.667 = $1,306.667

April 21, 2028 

$1,000.00 + applicable premium = $1,000.00 + $316.25 = $1,316.25

May 22, 2028 

$1,000.00 + applicable premium = $1,000.00 + $325.833 = $1,325.833

June 21, 2028 

$1,000.00 + applicable premium = $1,000.00 + $335.417 = $1,335.417

 

If, on any valuation date prior to the final valuation date, the closing value of any underlying is greater than or equal to its initial underlying value, but the closing value of any other underlying is less than its initial underlying value, you will not receive the premium indicated above following that valuation date. In order to receive the premium indicated above, the closing value of each underlying on the applicable valuation date must be greater than or equal to its initial underlying value.

 

 

 

 

 

 

 

 

 

 

 


 

Citigroup Global Markets Holdings Inc.

 

 

Payment at Maturity Diagram

The diagram below illustrates your payment at maturity of the securities, assuming the securities have not previously been automatically redeemed, for a range of hypothetical underlying returns of the worst performing underlying on the final valuation date. Your payment at maturity (if the securities are not earlier automatically redeemed) will be determined based solely on the performance of the worst performing underlying on the final valuation date.

Investors in the securities will not receive any dividends with respect to the underlyings. The diagram and examples below do not show any effect of lost dividend yield over the term of the securities. See “Summary Risk Factors—You will not receive dividends or have any other rights with respect to the underlyings” below.

Payment at Maturity Diagram

n The Securities

n The Worst Performing Underlying on the Final Valuation Date

 


 

Citigroup Global Markets Holdings Inc.

 

 

Hypothetical Examples of the Payment at Maturity

The examples below are intended to illustrate how, if the securities are not automatically redeemed prior to maturity, your payment at maturity will depend on the final underlying value of the worst performing underlying on the final valuation date. Your actual payment at maturity per security, if the securities are not automatically redeemed prior to maturity, will depend on the actual final underlying value of the worst performing underlying on the final valuation date. The examples are solely for illustrative purposes, do not show all possible outcomes and are not a prediction of any payment that may be made on the securities.

The examples below are based on the following hypothetical values and do not reflect the actual initial underlying values or final barrier values of the underlyings. For the actual initial underlying value and final barrier value of each underlying, see the cover page of this pricing supplement. We have used these hypothetical values, rather than the actual values, to simplify the calculations and aid understanding of how the securities work. However, you should understand that the actual payment at maturity on the securities will be calculated based on the actual initial underlying value and final barrier value of each underlying, and not the hypothetical values indicated below. For ease of analysis, figures below have been rounded.

 

Underlying

Hypothetical initial underlying value

Hypothetical final barrier value

Nasdaq-100 Index®

100.00

70.00 (70.00% of its hypothetical initial underlying value)

Russell 2000® Index

100.00

70.00 (70.00% of its hypothetical initial underlying value)

S&P 500® Index

100.00

70.00 (70.00% of its hypothetical initial underlying value)

 

Example 1—Upside Scenario. The final underlying value of the worst performing underlying on the final valuation date is 110.00, resulting in a 10.00% underlying return for the worst performing underlying on the final valuation date. In this example, the final underlying value of the worst performing underlying on the final valuation date is greater than its initial underlying value.

 

Underlying

Hypothetical final underlying value

Hypothetical underlying return

Nasdaq-100 Index® *

110.00

10.00%

Russell 2000® Index

130.00

30.00%

S&P 500® Index

140.00

40.00%

 

* Worst performing underlying on the final valuation date

Payment at maturity per security = $1,000 + the premium applicable to the final valuation date

= $1,000 + $345

= $1,345

In this scenario, because the final underlying value of the worst performing underlying on the final valuation date is greater than its initial underlying value, you would be repaid the stated principal amount of your securities at maturity plus the premium applicable to the final valuation date.

Example 2—Par Scenario. The final underlying value of the worst performing underlying on the final valuation date is 85.00, resulting in a -15.00% underlying return for the worst performing underlying on the final valuation date. In this example, the final underlying value of the worst performing underlying on the final valuation date is less than its initial underlying value but greater than its final barrier value.

 

Underlying

Hypothetical final underlying value

Hypothetical underlying return

Nasdaq-100 Index®

100.00

0.00%

Russell 2000® Index*

85.00

-15.00%

S&P 500® Index

120.00

20.00%

 

* Worst performing underlying on the final valuation date

Payment at maturity per security = $1,000

In this scenario, the worst performing underlying on the final valuation date has depreciated from its initial underlying value to its final underlying value so that its final underlying value is less than its initial underlying value but not below its final barrier value. As a result, you would be repaid the stated principal amount of your securities at maturity but would not receive any positive return on your investment.

Example 3—Downside Scenario. The final underlying value of the worst performing underlying on the final valuation date is 30.00, resulting in a -70.00% underlying return for the worst performing underlying on the final valuation date. In this example, the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value.

 

Underlying

Hypothetical final underlying value

Hypothetical underlying return

Nasdaq-100 Index®

130.00

30.00%

Russell 2000® Index

105.00

5.00%

S&P 500® Index*

30.00

-70.00%

 

* Worst performing underlying on the final valuation date

Payment at maturity per security = $1,000 + ($1,000 × the underlying return of the worst performing underlying on the final valuation date)

= $1,000 + ($1,000 × -70.00%)

= $1,000 + -$700.00

= $300.00


 

Citigroup Global Markets Holdings Inc.

 

 

In this scenario, the worst performing underlying on the final valuation date has depreciated from its initial underlying value to its final underlying value and its final underlying value is less than its final barrier value. As a result, your total return at maturity in this scenario would be negative and would reflect 1-to-1 exposure to the negative performance of the worst performing underlying on the final valuation date.


 

Citigroup Global Markets Holdings Inc.

 

 

Summary Risk Factors

An investment in the securities is significantly riskier than an investment in conventional debt securities. The securities are subject to all of the risks associated with an investment in our conventional debt securities (guaranteed by Citigroup Inc.), including the risk that we and Citigroup Inc. may default on our obligations under the securities, and are also subject to risks associated with each underlying. Accordingly, the securities are suitable only for investors who are capable of understanding the complexities and risks of the securities. You should consult your own financial, tax and legal advisors as to the risks of an investment in the securities and the suitability of the securities in light of your particular circumstances.

The following is a summary of certain key risk factors for investors in the securities. You should read this summary together with the more detailed description of risks relating to an investment in the securities contained in the section “Risk Factors Relating to the Securities” beginning on page EA-7 in the accompanying product supplement. You should also carefully read the risk factors included in the accompanying prospectus supplement and in the documents incorporated by reference in the accompanying prospectus, including Citigroup Inc.’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, which describe risks relating to the business of Citigroup Inc. more generally.

Citigroup Inc. will release quarterly earnings on July 15, 2025, which is during the marketing period and prior to the pricing date of these securities.

You may lose a significant portion or all of your investment. Unlike conventional debt securities, the securities do not provide for the repayment of the stated principal amount at maturity in all circumstances. If the securities are not automatically redeemed prior to maturity, your payment at maturity will depend on the final underlying value of the worst performing underlying on the final valuation date. If the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value, you will lose 1% of the stated principal amount of your securities for every 1% by which the worst performing underlying on the final valuation date has declined from its initial underlying value. There is no minimum payment at maturity on the securities, and you may lose up to all of your investment.

Your potential return on the securities is limited. Your potential return on the securities is limited to the applicable premium payable upon automatic early redemption or at maturity, as described on the cover page of this pricing supplement. If the closing value of the worst performing underlying on one of the valuation dates is greater than or equal to its initial underlying value, you will be repaid the stated principal amount of your securities and will receive the fixed premium applicable to that valuation date, regardless of how significantly the closing value of the worst performing underlying on that valuation date may exceed its initial underlying value. Accordingly, any premium may result in a return on the securities that is significantly less than the return you could have achieved on a direct investment in any or all of the underlyings.

The securities do not pay interest. Unlike conventional debt securities, the securities do not pay interest prior to maturity. You should not invest in the securities if you seek current income during the term of the securities.

The securities are subject to heightened risk because they have multiple underlyings. The securities are more risky than similar investments that may be available with only one underlying. With multiple underlyings, there is a greater chance that any one underlying will perform poorly, adversely affecting your return on the securities.

The securities are subject to the risks of each of the underlyings and will be negatively affected if any one underlying performs poorly. You are subject to risks associated with each of the underlyings. If any one underlying performs poorly, you will be negatively affected. The securities are not linked to a basket composed of the underlyings, where the blended performance of the underlyings would be better than the performance of the worst performing underlying alone. Instead, you are subject to the full risks of whichever of the underlyings is the worst performing underlying.

You will not benefit in any way from the performance of any better performing underlying. The return on the securities depends solely on the performance of the worst performing underlying, and you will not benefit in any way from the performance of any better performing underlying.

You will be subject to risks relating to the relationship between the underlyings. It is preferable from your perspective for the underlyings to be correlated with each other, in the sense that their closing values tend to increase or decrease at similar times and by similar magnitudes. By investing in the securities, you assume the risk that the underlyings will not exhibit this relationship. The less correlated the underlyings, the more likely it is that any one of the underlyings will perform poorly over the term of the securities. All that is necessary for the securities to perform poorly is for one of the underlyings to perform poorly. It is impossible to predict what the relationship between the underlyings will be over the term of the securities. The underlyings differ in significant ways and, therefore, may not be correlated with each other.

The securities may be automatically redeemed prior to maturity, limiting the term of the securities. If the closing value of the worst performing underlying on any valuation date (other than the final valuation date) is greater than or equal to its initial underlying value, the securities will be automatically redeemed. If the securities are automatically redeemed following any valuation date prior to the final valuation date, they will cease to be outstanding and you will not receive the premium applicable to any later valuation date. Moreover, you may not be able to reinvest your funds in another investment that provides a similar yield with a similar level of risk.

The securities offer downside exposure to the worst performing underlying, but no upside exposure to any underlying. You will not participate in any appreciation in the value of any underlying over the term of the securities. Consequently, your return on the securities will be limited to the applicable premium payable upon an automatic early redemption or at maturity and may be significantly less than the return on any underlying over the term of the securities.

You will not receive dividends or have any other rights with respect to the underlyings. You will not receive any dividends with respect to the underlyings. This lost dividend yield may be significant over the term of the securities. The payment scenarios described in


 

Citigroup Global Markets Holdings Inc.

 

 

this pricing supplement do not show any effect of such lost dividend yield over the term of the securities. In addition, you will not have voting rights or any other rights with respect to the underlyings or the stocks included in the underlyings.

The performance of the securities will depend on the closing values of the underlyings solely on the valuation dates, which makes the securities particularly sensitive to volatility in the closing values of the underlyings on or near the valuation dates. Whether the securities will be automatically redeemed prior to maturity will depend on the closing values of the underlyings solely on the valuation dates (other than the final valuation date), regardless of the closing values of the underlyings on other days during the term of the securities. If the securities are not automatically redeemed prior to maturity, what you receive at maturity will depend solely on the closing value of the worst performing underlying on the final valuation date, and not on any other day during the term of the securities. Because the performance of the securities depends on the closing values of the underlyings on a limited number of dates, the securities will be particularly sensitive to volatility in the closing values of the underlyings on or near the valuation dates. You should understand that the closing value of each underlying has historically been highly volatile.

The securities are subject to the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc. If we default on our obligations under the securities and Citigroup Inc. defaults on its guarantee obligations, you may not receive anything owed to you under the securities.

The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity. The securities will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. CGMI currently intends to make a secondary market in relation to the securities and to provide an indicative bid price for the securities on a daily basis. Any indicative bid price for the securities provided by CGMI will be determined in CGMI’s sole discretion, taking into account prevailing market conditions and other relevant factors, and will not be a representation by CGMI that the securities can be sold at that price, or at all. CGMI may suspend or terminate making a market and providing indicative bid prices without notice, at any time and for any reason. If CGMI suspends or terminates making a market, there may be no secondary market at all for the securities because it is likely that CGMI will be the only broker-dealer that is willing to buy your securities prior to maturity. Accordingly, an investor must be prepared to hold the securities until maturity.

The estimated value of the securities on the pricing date, based on CGMI’s proprietary pricing models and our internal funding rate, will be less than the issue price. The difference is attributable to certain costs associated with selling, structuring and hedging the securities that are included in the issue price. These costs include (i) any selling concessions or other fees paid in connection with the offering of the securities, (ii) hedging and other costs incurred by us and our affiliates in connection with the offering of the securities and (iii) the expected profit (which may be more or less than actual profit) to CGMI or other of our affiliates in connection with hedging our obligations under the securities. These costs adversely affect the economic terms of the securities because, if they were lower, the economic terms of the securities would be more favorable to you. The economic terms of the securities are also likely to be adversely affected by the use of our internal funding rate, rather than our secondary market rate, to price the securities. See “The estimated value of the securities would be lower if it were calculated based on our secondary market rate” below.

The estimated value of the securities was determined for us by our affiliate using proprietary pricing models. CGMI derived the estimated value disclosed on the cover page of this pricing supplement from its proprietary pricing models. In doing so, it may have made discretionary judgments about the inputs to its models, such as the volatility of, and correlation between, the closing values of the underlyings, dividend yields on the underlyings and interest rates. CGMI’s views on these inputs may differ from your or others’ views, and as an underwriter in this offering, CGMI’s interests may conflict with yours. Both the models and the inputs to the models may prove to be wrong and therefore not an accurate reflection of the value of the securities. Moreover, the estimated value of the securities set forth on the cover page of this pricing supplement may differ from the value that we or our affiliates may determine for the securities for other purposes, including for accounting purposes. You should not invest in the securities because of the estimated value of the securities. Instead, you should be willing to hold the securities to maturity irrespective of the initial estimated value.

The estimated value of the securities would be lower if it were calculated based on our secondary market rate. The estimated value of the securities included in this pricing supplement is calculated based on our internal funding rate, which is the rate at which we are willing to borrow funds through the issuance of the securities. Our internal funding rate is generally lower than our secondary market rate, which is the rate that CGMI will use in determining the value of the securities for purposes of any purchases of the securities from you in the secondary market. If the estimated value included in this pricing supplement were based on our secondary market rate, rather than our internal funding rate, it would likely be lower. We determine our internal funding rate based on factors such as the costs associated with the securities, which are generally higher than the costs associated with conventional debt securities, and our liquidity needs and preferences. Our internal funding rate is not an interest rate that is payable on the securities.

Because there is not an active market for traded instruments referencing our outstanding debt obligations, CGMI determines our secondary market rate based on the market price of traded instruments referencing the debt obligations of Citigroup Inc., our parent company and the guarantor of all payments due on the securities, but subject to adjustments that CGMI makes in its sole discretion. As a result, our secondary market rate is not a market-determined measure of our creditworthiness, but rather reflects the market’s perception of our parent company’s creditworthiness as adjusted for discretionary factors such as CGMI’s preferences with respect to purchasing the securities prior to maturity.

The estimated value of the securities is not an indication of the price, if any, at which CGMI or any other person may be willing to buy the securities from you in the secondary market. Any such secondary market price will fluctuate over the term of the securities based on the market and other factors described in the next risk factor. Moreover, unlike the estimated value included in this pricing supplement, any value of the securities determined for purposes of a secondary market transaction will be based on our secondary market rate, which will likely result in a lower value for the securities than if our internal funding rate were used. In addition, any secondary market price for the securities will be reduced by a bid-ask spread, which may vary depending on the aggregate stated


 

Citigroup Global Markets Holdings Inc.

 

 

principal amount of the securities to be purchased in the secondary market transaction, and the expected cost of unwinding related hedging transactions. As a result, it is likely that any secondary market price for the securities will be less than the issue price.

The value of the securities prior to maturity will fluctuate based on many unpredictable factors. The value of your securities prior to maturity will fluctuate based on the closing values of the underlyings, the volatility of, and correlation between, the closing values of the underlyings, dividend yields on the underlyings, interest rates generally, the time remaining to maturity and our and Citigroup Inc.’s creditworthiness, as reflected in our secondary market rate, among other factors described under “Risk Factors Relating to the Securities—Risk Factors Relating to All Securities—The value of your securities prior to maturity will fluctuate based on many unpredictable factors” in the accompanying product supplement. Changes in the closing values of the underlyings may not result in a comparable change in the value of your securities. You should understand that the value of your securities at any time prior to maturity may be significantly less than the issue price.

Immediately following issuance, any secondary market bid price provided by CGMI, and the value that will be indicated on any brokerage account statements prepared by CGMI or its affiliates, will reflect a temporary upward adjustment. The amount of this temporary upward adjustment will steadily decline to zero over the temporary adjustment period. See “Valuation of the Securities” in this pricing supplement.

The Russell 2000® Index is subject to risks associated with small capitalization stocks. The stocks that constitute the Russell 2000® Index are issued by companies with relatively small market capitalization. The stock prices of smaller companies may be more volatile than stock prices of large capitalization companies. These companies tend to be less well-established than large market capitalization companies. Small capitalization companies may be less able to withstand adverse economic, market, trade and competitive conditions relative to larger companies. Small capitalization companies are less likely to pay dividends on their stocks, and the presence of a dividend payment could be a factor that limits downward stock price pressure under adverse market conditions.

Our offering of the securities is not a recommendation of any underlying. The fact that we are offering the securities does not mean that we believe that investing in an instrument linked to the underlyings is likely to achieve favorable returns. In fact, as we are part of a global financial institution, our affiliates may have positions (including short positions) in the underlyings or in instruments related to the underlyings, and may publish research or express opinions, that in each case are inconsistent with an investment linked to the underlyings. These and other activities of our affiliates may affect the closing values of the underlyings in a way that negatively affects the value of and your return on the securities.

The closing value of an underlying may be adversely affected by our or our affiliates’ hedging and other trading activities. We expect to hedge our obligations under the securities through CGMI or other of our affiliates, who may take positions in the underlyings or in financial instruments related to the underlyings and may adjust such positions during the term of the securities. Our affiliates also take positions in the underlyings or in financial instruments related to the underlyings on a regular basis (taking long or short positions or both), for their accounts, for other accounts under their management or to facilitate transactions on behalf of customers. These activities could affect the closing values of the underlyings in a way that negatively affects the value of and your return on the securities. They could also result in substantial returns for us or our affiliates while the value of the securities declines.

We and our affiliates may have economic interests that are adverse to yours as a result of our affiliates’ business activities. Our affiliates engage in business activities with a wide range of companies. These activities include extending loans, making and facilitating investments, underwriting securities offerings and providing advisory services. These activities could involve or affect the underlyings in a way that negatively affects the value of and your return on the securities. They could also result in substantial returns for us or our affiliates while the value of the securities declines. In addition, in the course of this business, we or our affiliates may acquire non-public information, which will not be disclosed to you.

The calculation agent, which is an affiliate of ours, will make important determinations with respect to the securities. If certain events occur during the term of the securities, such as market disruption events and other events with respect to an underlying, CGMI, as calculation agent, will be required to make discretionary judgments that could significantly affect your return on the securities. In making these judgments, the calculation agent’s interests as an affiliate of ours could be adverse to your interests as a holder of the securities. See “Risk Factors Relating to the Securities—Risk Factors Relating to All Securities—The calculation agent, which is an affiliate of ours, will make important determinations with respect to the securities” in the accompanying product supplement.

Changes that affect the underlyings may affect the value of your securities. The sponsors of the underlyings may at any time make methodological changes or other changes in the manner in which they operate that could affect the values of the underlyings. We are not affiliated with any such underlying sponsor and, accordingly, we have no control over any changes any such sponsor may make. Such changes could adversely affect the performance of the underlyings and the value of and your return on the securities.

The U.S. federal tax consequences of an investment in the securities are unclear. There is no direct legal authority regarding the proper U.S. federal tax treatment of the securities, and we do not plan to request a ruling from the Internal Revenue Service (the “IRS”). Consequently, significant aspects of the tax treatment of the securities are uncertain, and the IRS or a court might not agree with the treatment of the securities as prepaid forward contracts. If the IRS were successful in asserting an alternative treatment of the securities, the tax consequences of the ownership and disposition of the securities might be materially and adversely affected. Moreover, future legislation, Treasury regulations or IRS guidance could adversely affect the U.S. federal tax treatment of the securities, possibly retroactively.

If you are a non-U.S. investor, you should review the discussion of withholding tax issues in “United States Federal Tax Considerations—Non-U.S. Holders” below.

You should read carefully the discussion under “United States Federal Tax Considerations” and “Risk Factors Relating to the Securities” in the accompanying product supplement and “United States Federal Tax Considerations” in this pricing supplement. You should also


 

Citigroup Global Markets Holdings Inc.

 

 

consult your tax adviser regarding the U.S. federal tax consequences of an investment in the securities, as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the Nasdaq-100 Index®

The Nasdaq-100 Index® is a modified market capitalization-weighted index of stocks of the 100 largest non-financial companies listed on the Nasdaq Stock Market. All stocks included in the Nasdaq-100 Index® are traded on a major U.S. exchange. The Nasdaq-100 Index® was developed by the Nasdaq Stock Market, Inc. and is calculated, maintained and published by Nasdaq, Inc.

Please refer to the section “Equity Index Descriptions— The Nasdaq-100 Index®” in the accompanying underlying supplement for additional information.

We have derived all information regarding the Nasdaq-100 Index® from publicly available information and have not independently verified any information regarding the Nasdaq-100 Index®. This pricing supplement relates only to the securities and not to the Nasdaq-100 Index®. We make no representation as to the performance of the Nasdaq-100 Index® over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the Nasdaq-100 Index® is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the Nasdaq-100 Index® on July 10, 2025 was 22,829.26.

The graph below shows the closing value of the Nasdaq-100 Index® for each day such value was available from January 2, 2015 to July 10, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

Nasdaq-100 Index® – Historical Closing Values
January 2, 2015 to July 10, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the Russell 2000® Index

The Russell 2000® Index is designed to track the performance of the small capitalization segment of the U.S. equity market. All stocks included in the Russell 2000® Index are traded on a major U.S. exchange. It is calculated and maintained by FTSE Russell.

Please refer to the section “Equity Index Descriptions— The Russell Indices” in the accompanying underlying supplement for additional information.

We have derived all information regarding the Russell 2000® Index from publicly available information and have not independently verified any information regarding the Russell 2000® Index. This pricing supplement relates only to the securities and not to the Russell 2000® Index. We make no representation as to the performance of the Russell 2000® Index over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the Russell 2000® Index is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the Russell 2000® Index on July 10, 2025 was 2,263.410.

The graph below shows the closing value of the Russell 2000® Index for each day such value was available from January 2, 2015 to July 10, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

Russell 2000® Index – Historical Closing Values
January 2, 2015 to July 10, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the S&P 500® Index

The S&P 500® Index consists of the common stocks of 500 issuers selected to provide a performance benchmark for the large capitalization segment of the U.S. equity markets. It is calculated and maintained by S&P Dow Jones Indices LLC.

Please refer to the section “Equity Index Descriptions— The S&P U.S. Indices” in the accompanying underlying supplement for additional information.

We have derived all information regarding the S&P 500® Index from publicly available information and have not independently verified any information regarding the S&P 500® Index. This pricing supplement relates only to the securities and not to the S&P 500® Index. We make no representation as to the performance of the S&P 500® Index over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the S&P 500® Index is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the S&P 500® Index on July 10, 2025 was 6,280.46.

The graph below shows the closing value of the S&P 500® Index for each day such value was available from January 2, 2015 to July 10, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

S&P 500® Index – Historical Closing Values
January 2, 2015 to July 10, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

United States Federal Tax Considerations

You should read carefully the discussion under “United States Federal Tax Considerations” and “Risk Factors Relating to the Securities” in the accompanying product supplement and “Summary Risk Factors” in this pricing supplement.

In the opinion of our counsel, Davis Polk & Wardwell LLP, a security should be treated as a prepaid forward contract for U.S. federal income tax purposes. By purchasing a security, you agree (in the absence of an administrative determination or judicial ruling to the contrary) to this treatment. There is uncertainty regarding this treatment, and the IRS or a court might not agree with it. Moreover, our counsel’s opinion is based on market conditions as of the date of this preliminary pricing supplement and is subject to confirmation on the pricing date.

Assuming this treatment of the securities is respected and subject to the discussion in “United States Federal Tax Considerations” in the accompanying product supplement, the following U.S. federal income tax consequences should result under current law:

You should not recognize taxable income over the term of the securities prior to maturity, other than pursuant to a sale or exchange.

Upon a sale or exchange of a security (including retirement at maturity), you should recognize capital gain or loss equal to the difference between the amount realized and your tax basis in the security. Such gain or loss should be long-term capital gain or loss if you held the security for more than one year.

We do not plan to request a ruling from the IRS regarding the treatment of the securities. An alternative characterization of the securities could materially and adversely affect the tax consequences of ownership and disposition of the securities, including the timing and character of income recognized. In addition, the U.S. Treasury Department and the IRS have requested comments on various issues regarding the U.S. federal income tax treatment of “prepaid forward contracts” and similar financial instruments and have indicated that such transactions may be the subject of future regulations or other guidance. Furthermore, members of Congress have proposed legislative changes to the tax treatment of derivative contracts. Any legislation, Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect. You should consult your tax adviser regarding possible alternative tax treatments of the securities and potential changes in applicable law.

Non-U.S. Holders. Subject to the discussions below and in “United States Federal Tax Considerations” in the accompanying product supplement, if you are a Non-U.S. Holder (as defined in the accompanying product supplement) of the securities, you generally should not be subject to U.S. federal withholding or income tax in respect of any amount paid to you with respect to the securities, provided that (i) income in respect of the securities is not effectively connected with your conduct of a trade or business in the United States, and (ii) you comply with the applicable certification requirements.

As discussed under “United States Federal Tax Considerations—Tax Consequences to Non-U.S. Holders” in the accompanying product supplement, Section 871(m) of the Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities (“U.S. Underlying Equities”) or indices that include U.S. Underlying Equities. Section 871(m) generally applies to instruments that substantially replicate the economic performance of one or more U.S. Underlying Equities, as determined based on tests set forth in the applicable Treasury regulations. However, the regulations, as modified by an IRS notice, exempt financial instruments issued prior to January 1, 2027 that do not have a “delta” of one. Based on the terms of the securities and representations provided by us as of the date of this preliminary pricing supplement, our counsel is of the opinion that the securities should not be treated as transactions that have a “delta” of one within the meaning of the regulations with respect to any U.S. Underlying Equity and, therefore, should not be subject to withholding tax under Section 871(m). However, the final determination regarding the treatment of the securities under Section 871(m) will be made as of the pricing date for the securities, and it is possible that the securities will be subject to withholding tax under Section 871(m) based on the circumstances as of that date.

A determination that the securities are not subject to Section 871(m) is not binding on the IRS, and the IRS may disagree with this treatment. Moreover, Section 871(m) is complex and its application may depend on your particular circumstances, including your other transactions. You should consult your tax adviser regarding the potential application of Section 871(m) to the securities.

If withholding tax applies to the securities, we will not be required to pay any additional amounts with respect to amounts withheld.

You should read the section entitled “United States Federal Tax Considerations” in the accompanying product supplement. The preceding discussion, when read in combination with that section, constitutes the full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of owning and disposing of the securities.

You should also consult your tax adviser regarding all aspects of the U.S. federal income and estate tax consequences of an investment in the securities and any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.

Supplemental Plan of Distribution

CGMI, an affiliate of Citigroup Global Markets Holdings Inc. and the underwriter of the sale of the securities, is acting as principal and will receive an underwriting fee of up to $27.50 for each security sold in this offering. The actual underwriting fee will be equal to the selling concession provided to selected dealers, as described in this paragraph. From this underwriting fee, CGMI will pay selected dealers not affiliated with CGMI a variable selling concession of up to $27.50 for each security they sell. For the avoidance of doubt, any fees or selling concessions described in this pricing supplement will not be rebated if the securities are automatically redeemed prior to maturity.

See “Plan of Distribution; Conflicts of Interest” in the accompanying product supplement and “Plan of Distribution” in each of the accompanying prospectus supplement and prospectus for additional information.


 

Citigroup Global Markets Holdings Inc.

 

 

Valuation of the Securities

CGMI calculated the estimated value of the securities set forth on the cover page of this pricing supplement based on proprietary pricing models. CGMI’s proprietary pricing models generated an estimated value for the securities by estimating the value of a hypothetical package of financial instruments that would replicate the payout on the securities, which consists of a fixed-income bond (the “bond component”) and one or more derivative instruments underlying the economic terms of the securities (the “derivative component”). CGMI calculated the estimated value of the bond component using a discount rate based on our internal funding rate. CGMI calculated the estimated value of the derivative component based on a proprietary derivative-pricing model, which generated a theoretical price for the instruments that constitute the derivative component based on various inputs, including the factors described under “Summary Risk Factors—The value of the securities prior to maturity will fluctuate based on many unpredictable factors” in this pricing supplement, but not including our or Citigroup Inc.’s creditworthiness. These inputs may be market-observable or may be based on assumptions made by CGMI in its discretionary judgment.

The estimated value of the securities is a function of the terms of the securities and the inputs to CGMI’s proprietary pricing models.  As of the date of this preliminary pricing supplement, it is uncertain what the estimated value of the securities will be on the pricing date because it is uncertain what the values of the inputs to CGMI’s proprietary pricing models will be on the pricing date.

For a period of approximately three months following issuance of the securities, the price, if any, at which CGMI would be willing to buy the securities from investors, and the value that will be indicated for the securities on any brokerage account statements prepared by CGMI or its affiliates (which value CGMI may also publish through one or more financial information vendors), will reflect a temporary upward adjustment from the price or value that would otherwise be determined. This temporary upward adjustment represents a portion of the hedging profit expected to be realized by CGMI or its affiliates over the term of the securities. The amount of this temporary upward adjustment will decline to zero on a straight-line basis over the three-month temporary adjustment period. However, CGMI is not obligated to buy the securities from investors at any time.  See “Summary Risk Factors—The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity.”

Contact

Clients may contact their local brokerage representative. Third-party distributors may contact Citi Structured Investment Sales at (212) 723-7005.

© 2025 Citigroup Global Markets Inc. All rights reserved. Citi and Citi and Arc Design are trademarks and service marks of Citigroup Inc. or its affiliates and are used and registered throughout the world.

FAQ

How much cash does Lexaria Bioscience (LEXX) have as of May 31 2025?

Lexaria reported $4.59 million in cash, down from $6.50 million at August 31 2024.

Did Lexaria generate a profit in Q3 FY-2025?

No. The company posted a net loss of $3.79 million for the quarter and $9.21 million for the nine-month period.

What is the status of Lexaria’s GLP-1 oral drug programs?

Human pilot studies with DehydraTECH-tirzepatide and DehydraTECH-liraglutide showed fewer adverse events vs injectables; a 120-subject Phase 1b (GLP-1-H24-4) is over 50% dosed with full results expected Q4 2025.

Why is there a going-concern warning in the 10-Q?

Management states that current cash plus expected licensing inflows are insufficient to cover obligations for 12 months, creating substantial doubt about the company’s ability to continue without new financing.

How many shares and warrants are outstanding after recent financings?

As of July 11 2025, 19,559,179 common shares are issued; 7,298,171 warrants remain outstanding with a weighted average exercise price of $3.75.

What percentage of revenue comes from Lexaria’s top customers?

Two customers accounted for 100% of revenue in the nine months ended May 31 2025.
Citigroup Inc

NYSE:C

C Rankings

C Latest News

C Latest SEC Filings

C Stock Data

176.71B
1.83B
1.01%
76.85%
1.81%
Banks - Diversified
National Commercial Banks
United States
NEW YORK